Although targeted therapies such as the HER2-targeted monoclonal antibody–drug conjugate trastuzumab–deruxtecan have improved outcomes, challenges remain because of treatment-related adverse events and tumor resistance to HER2 blockade in HER2-positive advanced-stage breast cancer (2). Here, ERBB2 is linked to breast carcinoma.